Briefing: Eli Lilly’s ‘triple-G’ shows potency, raises concerns

Eli Lilly's 'triple-G' drug has recently demonstrated notable potency in clinical assessments, indicating potential for impactful therapeutic applications.

In parallel, advancements in In-vivo CAR-T technology are progressing towards clinical reality, which may alter treatment paradigms in oncology.

However, these developments also prompt a need for careful evaluation of safety, efficacy, and long-term implications for healthcare infrastructure and patient management.